TRX103
Phase 2Cell therapy
TRX103 is one of 74 biologic programs targeting Hematopoietic Stem Cell Transplant (HSCT). It is currently in Phase 2.
3
Indications
3
Total Trials
3
Active Trials
73
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
74 competitors in Crohn's Disease
#DrugCompanyPhaseTrials
1Remicade
Johnson & JohnsonApproved
Humira
NovartisApproved
Stelara
Johnson & JohnsonApproved
Entyvio
TakedaApproved
Omvoh
Eli LillyApproved
Imuran
LLegacy Health System
Approved
Rocaltrol
Jazz PharmaceuticalsApproved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Medrol
PfizerApproved
Flagyl
DDePuy Orthopaedics
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hematopoietic Stem Cell Transplant (HSCT)1 trial
Uveitis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TRX103. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 2[1]
- Company
- TTr1X, Inc.